Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galera Therapeutics Inc
GRTX | US
0.04
USD0
0%
GRTX | US
About Galera Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.04
Open
0.04
High
0.04
Low
0.04
Galera Therapeutics Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419) a small molecule dismutase mimetic which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711 a dismutase mimetic product candidate which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern Pennsylvania.
View LessGRTX | US
Risk
171.1
Sharpe
0.01
Luna's Score
37/100
Recommendation
Sell
Luna says (GRTX | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
175.4%1 month
171.1%3 months
132.3%6 months
141.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
29.39
Debt to equity
-0.01
Debt to assets
0.07
Ent. to EBITDA
-0.70
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-24.81M
MarketCap
2.22M
MarketCap(USD)
2.22M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.06K
Short ratio
1.16
Short perc.
5.28
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.02
Range1M
0.03
Range3M
0.03
Volumes: Market Activity
Rel. volume
0.01
Price X volume
20.20
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.70 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 29.39 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 132.34 | 72.80 | Riskier |
| Debt to Equity | -0.01 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 2.22M | 3.66B | Emerging |
